PTO/SB/08A (07-05) Approved for use through 07/31/2006

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Sheet

(use as many sheets as necessary)

of

2

Complete if Known			
Application Number	10/575,913		
Filing Date	April 13, 2006		
First Named Inventor	John Brew		
Art Unit	Not yet assigned		
Examiner Name	Not yet assigned		
Attorney Docket Number	G.IF-7489		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Document Number Number - Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
/K.C./	U1	US-5,543,434 A1	08-06-1996	Stuart L, Weg	All	
/K.C./	U2	US-6,538,008 B1	03-25-2003	Susan Boyce	All	
	U3	US-				
	U4	US-				
	U5	US-				
	U6	US-				
	U7	US-				
	U8	US-				
	U9	US-				
	U10	US-				
	U11	US-				
	U12	US-				
	U13	US-				
	U14	US-				
	U15	US-				
	U16	US-				
	U17	US-				

		FOREIGN Foreign Patent Document						_
Examiner Initials*	Cite No. 1	Country Co		ind Code ⁶ (# known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	١,
/K.C./	F1	JP	11 029 476		02-02-1999	Grelan Pharmaceut. Co. Ltd.	Abstract	
/K.C./	F2	wo	99/13799	A1	03-25-1999	Euro-Celtique, S.A.	All	
/K.C./	F3	wo	99/18967	A1	04-22-1999	Panos Therapeutics Ltd.	All	П
/K.C./	F4	wo	03/072057	A2	09-04-2003	Univ. of TX Systems, Board of Regents	All	
/K.C./	F5	wo	03/092689	A1	11-13-2003	Arakis LTD.	All	П
/K.C./	F6							1

Examiner Signature	/Kathrien Cruz/	Date Considered	12/03/2008

"EXAMINET: Initial f reterrons considered, whether or not classion is nonformance with MPEP 808. Daw line through classion if not in conformance and not considered, instead copy of this form with next communication to applicant." Applicant's unique distinct designation number (optional). See Rifed Codes of USPTO "Annual Codes of USPTO" and the Communication of the Codes of USPTO" and the Communication of the Codes of USPTO" and USPTO" and

This collection of information is required by 37 CFR, 197 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO in process) an application. Confiderfield by so governed by 35 U.S. C. 122 and 37 CFR, 114. This collection is estimated to 50 boxers to complexe, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of the your require to complete this form and/or suppositions for modular gibb unders, should be sent to the Chief Information Cifect, U.S. Peatla and Trademark Office, P.O. Box 1450, Alexandrie, VA. 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandrie, VA. 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

Complete if Known			
Application Number	10/575,913	_	
Filing Date	April 13, 2006	_	
First Named Inventor	John Brew	_	
Art Unit	Not yet assigned	_	
Examiner Name	Not yet assigned	_	
Attorney Docket Number	G IE 7490	_	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
/K.C./	R1	BERNARDI, MARA: ALFIO BERTOLINI: KRYSTYNA SZCZAWINSKA: SUSANNA GENEDANI (1998) *Blockade of the polyamine site of NMDA receptors produces antinociception and enhances the effect of morphine, in mice *European Journal of Pharmacology 298.51-55, (Elsevier, publisher).	
/K.C./	R2	KOZELA, E. and P. POPIK, Published on line August 9, 2002, © Springer-Verlag, "The effects of NMDA receptor antagonists on acute morphine antinociception in mice" <i>Amino Acids</i> 23:163-168, printed in Australia.	
/K.C./	R3	REDWINE et al., "Effects of NMDA receptor antagonists on acute μ-opioid analgesia in the rat," <i>Pharmacology, Biochemistry and Behavior</i> , 2003, pp. 361-372, Vol. 76.	
	R4		
	R5		-
	R6		
	R7		
	R8		
	R9		-
	R10	· ·	

$\overline{}$				
Examiner Signature	/Kathrien Cruz/	Date Considered	12/03/2008	
ACMAN MICH.				

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

^{*}EXAMINER: Initial if inference considered, whether or not clation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with need communication to applicant in solutions of the conformance and not considered. Include copy of this form with need communication to applicant is not placed as the conformance and the conformance are conformanced as the conformance and the conformance are conformanced as the conformanced as the conformance are conformanced as the conformanced as the conformanced as the conformance are conformanced as the conformanced as the conformance are conformanced as the conformanced as the conformanced as the confor amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450, D